2nd Quarter - Report

PURDUE PHARMA, LP for PURDUE PHARMA LP

Period 2nd Quarter 2020 Filed Jul 21, 2020 Signed by Matthew O'Donnell

Official filing
Firm
PURDUE PHARMA, LP
Client
PURDUE PHARMA LP
Income
—
Expenses
$240,733
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R.4710 - Pharmaceutical Independence Long-Term Readiness Reform Act and H.R.6482 - Protecting Our Pharmaceutical Supply Chain from China Act of 2020; monitoring activity regarding potential incentives to increase domestic manufacturing of pharmaceutical products. S. 2543 Prescription Drug Pricing Reduction Act of 2019; monitoring to understand potential new obligations on pharmaceutical manufacturers regarding price transparency and implications for applicable federal programs.

LobbyistCovered position, as disclosed
KATHLEEN KONKA New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 4710 (116th), S. 2543 (116th), H.R. 6482 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.